Home / Biopharma / Stocks Ensnare on Profitability Ratio: Exelixis, Inc. (NASDAQ:EXEL), Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Stocks Ensnare on Profitability Ratio: Exelixis, Inc. (NASDAQ:EXEL), Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Waking on tracing line of previous stocks, Exelixis, Inc. (NASDAQ:EXEL) also making a luring appeal, share price swings at $16.92 with percentage change of -0.41% in most recent trading session.

Gross profit margin, is its sub parts that firm has 95.40%. Moving toward returns ratio, EXEL has returns on investment of -43.80% which indicates firm’s investment efficiency or to compare the efficiency of a number of different investments.

While returns on assets calculated as -36.00% hat gives an idea about how efficient management is at using its assets to generate earnings. It has returns on equity of 160.90%, which is measuring a corporation’s profitability by revealing how much profit generates by EXEL with the shareholders’ money. The firm attains analyst recommendation of 1.50 on scale of 1-5 with week’s performance of 4.12%.

Moving toward ratio analysis, it has current ratio of 2.10 and quick ratio was calculated as 2.10. The debt to equity ratio appeared as 5.97 for seeing its liquidity position. The firm attains analyst recommendation of 1.50 out of 1-5 scale with week’s performance of 4.12%.

Moving on tracing line, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) need to consider for profitability analysis, in latest session share price swings at $101.86 with percentage change of -1.49%.

The Co has positive 4.80% profit margin to find consistent trends in a firm’s earnings. Gross profit margin and operating profit margin are its sub parts that firm have 68.10% and 11.30% respectively. ZBH has returns on investment of 2.20%. The returns on assets was 1.40% that gives an idea about how efficient management is at using its assets to generate earnings. It has returns on equity of 3.70%, which is measuring profitability by disclosing how much profit generates by ZBH with the shareholders’ money.

The firm attains analyst recommendation of 2.00 on scale of 1-5 with week’s performance of 1.04%. The firm current ratio calculated as 2.00, this value is acceptable if it lies in 1.3% to 3%. But its varies industry to industry. To strengthen these views, active industry firm has Quick Ratio of 1.10, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 1.19, sometimes its remain same with long term debt to equity ratio.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Check Also

Stocks worth Investment with best Profit Margins: Novo Nordisk (NYSE:NVO), Endo International (NASDAQ:ENDP)

Novo Nordisk A/S (NYSE:NVO) runs in leading trade, it inching down -0.65% to traded at …

Leave a Reply

Your email address will not be published. Required fields are marked *